---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-029524"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:57:26.466246+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028

## Summary
- Net product revenue $20.0M (up 15% YoY from $17.4M).
- Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).
- Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.
- LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end.

## SEC filing metadata
- accession: 0001628280-26-029524
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adc-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-029524
- JSON: https://secwatch.observer/filing/0001628280-26-029524.json
- Plain text: https://secwatch.observer/filing/0001628280-26-029524.txt

## Key facts
- Earnings Releases
  ADC Therapeutics SA reported the first quarter ended March 31, 2026 results: revenue $20.0 million, net income $33.0 million, EPS $0.21 per basic and diluted share.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $20.0 million
  - Net income: $33.0 million
  - EPS: $0.21 per basic and diluted share
  - Result: reported results
  source text: Updates LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.